First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimo Di Maïo(University of Siena), Ronald Feld(University Health Network), Saverio Cinieri(Ospedale A. Perrino), Floriana Morgillo(University of Campania "Luigi Vanvitelli"), Raffaella Felletti(Apple (Israel)), Natasha B. Leighl(Princess Margaret Cancer Centre), Vittorio Gebbia(Università degli Studi di Enna Kore), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Giovenzio Genestreti(Apple (Israel)), Paolo Maione(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Salvatore Siena(University of Milan), Antônio Rossi(Università Campus Bio-Medico), Gianfranco Mancuso, Giampaolo Tortora(University of Naples Federico II), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Adolfo Favaretto(Istituto Oncologico Veneto), Flavia Cantile(Apple (Israel)), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Maria Carmela Piccirillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ming‐Sound Tsao(Kumamoto University), Mauro Saieg(University Health Network), Gilda da Cunha Santos(University Health Network), Yasmin Alam(Ottawa Hospital), Charles Butts(Apple (Israel)), Rafal Wierzbicki(King Faisal Specialist Hospital & Research Centre), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 234
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k